AKT1 and central nervous system cancer: In summary, trimebutine can inhibit glioma/glioblastoma cell migration and proliferation, and promote cell apoptosis through regulating the MAPK/ERK and PI3K/AKT signaling pathways, suggesting that trimebutine may represent a novel therapy for malignant glioma.